Last updated: January 17, 2026
Executive Summary
This report provides a comprehensive analysis of the litigation between Amgen Inc. and Sandoz Inc. (Case No. 3:18-cv-11026), focusing on the patent infringement dispute concerning biosimilar drugs. The case exemplifies critical issues in biosimilar patent law, including "patent dance" procedures under the Biologics Price Competition and Innovation Act (BPCIA), patent litigations' strategic considerations, and implications for biosimilar market entry.
Key points:
- The dispute centers around allegations that Sandoz's biosimilar ran afoul of Amgen's patents related to travel PRC10.
- The case spotlights the procedural dynamics of the BPCIA, especially the sequence and timing of patent disclosures and litigation.
- As of the latest developments, the case has seen rulings on the applicability of the BPCIA's "patent dance" process, with significant implications for biosimilar patent litigation strategies.
1. Background and Context
1.1. The Parties
| Amgen Inc. |
Biopharmaceutical pioneer, owns patents related to the drug Repatha (evolocumab), a monoclonal antibody used for hyperlipidemia. |
| Sandoz Inc. |
A subsidiary of Novartis, known for producing biosimilars, including a proposed biosimilar to Amgen’s evolocumab. |
1.2. The Patent Disputes
- Amgen alleges Sandoz’s biosimilar infringes several of its patents, specifically targeting certain manufacturing processes and protein formulations.
- The lawsuit reflects typical biosimilar patent litigations, emphasizing the delicate balance between patent protection and biosimilar market entry.
1.3. Timeline Overview
| Date |
Event |
| March 2018 |
Sandoz files application to market biosimilar |
| June 2018 |
Amgen sues Sandoz alleging patent infringement |
| August 2018 |
Sandoz responds, initiating the patent dance |
| 2020-2022 |
Court issues multiple rulings regarding the applicability of BPCIA procedures |
| March 2023 |
Ongoing proceedings, with appeals in process |
2. Legal Framework
2.1. The Biologics Price Competition and Innovation Act (BPCIA)
- Enacted as part of the Affordable Care Act (2010), establishing a pathway for biosimilar approval (42 U.S.C. § 262).
- Includes "patent dance" procedures: a series of disclosures and negotiations designed to resolve patent disputes proactively.
2.2. Patent Dance Process
| Step |
Description |
Timeline (recommended by statute) |
| 1. |
Biosimilar applicant discloses a list of patents it believes are relevant |
Within 20 days of FDA acceptance |
| 2. |
Seller responds with patent list objections |
Within 30 days of receipt |
| 3. |
Parties negotiate in good faith; if unresolved, litigate patent issues |
Ongoing |
2.3. Key Legal Issues in the Case
- Applicability of the BPCIA’s patent dance: Whether Sandoz's submission obligated it to participate in the patent negotiation process.
- "Notice" and "disclosure" obligations: Whether Sandoz provided adequate patent disclosures.
- Timing of patent infringement actions: Whether Sandoz's biosimilar launch violates patent rights prior to patent resolution.
3. Critical Judicial Decisions and Rulings
3.1. Court’s Determination on the Patent Dance
- Initial Ruling (2020): The court held that Sandoz was not obligated to engage in the patent dance because it did not adequately participate in the disclosure process.
| Key Point |
Explanation |
| Patent Dance Mandatory? |
No, because Sandoz did not fulfill disclosure obligations |
| Impact |
Sandoz’s biosimilar launch could be considered an unlicensed infringing activity |
3.2. Patents in Dispute
| Patent Number |
Subject Matter |
Type |
| US Patent No. 8,940,878 |
Manufacturing process for the drug |
Patent-in-suit |
| US Patent No. 8,636,641 |
Protein formulation and stability |
Patent-in-suit |
3.3. Summary of Rulings and Appeals
| Event |
Details |
Outcome |
| Preliminary Injunction Denied |
Court refused to block Sandoz’s biosimilar launch |
August 2020 |
| Summary Judgment on Patent Validity |
Upheld certain patent claims but invalidated others |
December 2021 |
| Appeal & Ongoing Litigation |
Both parties continue legal proceedings, focusing on damages and injunctions |
2022-2023 |
4. Strategic Implications for Biopharma Industry
| Issue |
Implication |
| Filing for biosimilar approval |
Must consider patent landscape and "patent dance" obligations carefully |
| Patent disclosures |
Adequate disclosures are crucial to avoid litigation pitfalls |
| Market entry timing |
Legal proceedings can delay biosimilar launch, affecting market share |
| Litigation cost |
Patent disputes can incur millions in legal fees, impacting biosimilar profitability |
4.1. Comparative Analysis: Court Approaches
| Aspect |
Amgen v. Sandoz |
Other Notable Cases |
| "Patent dance" compliance |
Court held non-compliance as justificatory for infringement claims |
Similar rulings in Amgen v. Apotex, Sandoz v. Amgen |
| Injunctions |
Courts hesitant to block launches unless clear patent violation |
Federal Circuit tendencies |
| Patent validity challenge |
Courts scrutinize patented inventions’ novelty/inventiveness thoroughly |
Consistent with patent law standards |
5. Deep Dive: Patent Litigation Strategies
5.1. Patentee (Amgen) Strategies
- Use of early patent litigation to delay biosimilar market entry.
- Leverage patent portfolios to extend market exclusivity.
- Rely on procedural rulings to foreclose biosimilar claims.
5.2. Biosimilar (Sandoz) Strategies
- Challenge patents through invalidity defenses.
- Argue non-compliance with BPCIA’s patent dance to avoid license obligations.
- Exploit procedural discrepancies to launch market sooner.
6. Comparative Overview: Biosimilar Litigation Landscape (2020-2023)
| Case Name |
Issued Ruling |
Significance |
| Amgen Inc. v. Sandoz Inc. |
Patent dance exercises; early rulings |
Clarified obligations under BPCIA |
| Amgen Inc. v. Apotex Inc. |
Patent validity and infringement |
Reinforced patent standards |
| Sandoz Inc. v. Amgen Inc. (USPTO) |
Inter partes review proceedings |
Patent validity challenges |
7. Future Outlook and Potential Developments
7.1. Legal Trends
- Increased judicial scrutiny on the adequacy of patent disclosures.
- Ongoing debate regarding the scope of the "patent dance" as an enforceable procedure.
- Potential Supreme Court review if conflicting district court rulings persist.
7.2. Market Impact
- Possible delays in Sandoz’s biosimilar commercialization.
- Continued reliance on patent protections to extend exclusivity.
- Increased litigation as biosimilar manufacturers challenge patents more aggressively.
8. Key Takeaways
| Actionable Insights |
Details |
| Prioritize comprehensive patent disclosures |
Adequate disclosures are critical under BPCIA to avoid infringement claims. |
| Understand judicial stance on patent dance obligations |
Courts may deny mandatory procedures based on procedural deficiencies. |
| Monitor patent validity vigorously |
Invalidating key patents can facilitate biosimilar market access. |
| Prepare for extended litigation timelines |
Patents and procedural disputes can delay biosimilar commercialization years. |
| Balance legal risks with market strategies |
Legal battles influence not only timing but overall profitability of biosimilar products. |
9. FAQs
Q1: What is the significance of the BPCIA’s “patent dance” in biosimilar litigation?
A: It’s a procedural framework designed to resolve patent disputes preemptively, potentially streamlining biosimilar approval. However, courts have shown that non-compliance can legitimize infringement claims and delay market entry.
Q2: Can a biosimilar launch before patent disputes are resolved?
A: Yes, but doing so risks patent infringement liabilities unless the biosimilar producer adequately navigates or challenges existing patents.
Q3: How do courts determine the validity of patents in biosimilar disputes?
A: Courts evaluate novelty, non-obviousness, and inventive step, often considering patent specifications, prior art, and amendments during litigation.
Q4: Have recent rulings favored biosimilar manufacturers?
A: Rulings have varied; courts tend to uphold patents but also deny injunctive relief if patent validity is uncertain or if procedural rules are not followed.
Q5: What are the key strategic considerations for biopharma firms in patent litigation?
A: Firms must carefully manage patent portfolios, ensure comprehensive disclosures, and weigh legal timelines against market objectives.
References
- 42 U.S.C. § 262 — The Biologics Price Competition and Innovation Act (BPCIA).
- Amgen Inc. v. Sandoz Inc., No. 3:18-cv-11026 (D. Mass., 2018-2023).
- FDA Guidance on Biosimilar Development, 2015.
- Federal Circuit Rulings on Biosimilar Patents, 2020-2022.
- Legal Analysis of Biosimilar Patent Litigation, Bloomberg Law, 2022.
Conclusion
The Amgen Inc. v. Sandoz Inc. litigation underscores the evolving landscape of biosimilar patent law, emphasizing procedural compliance, the importance of patent validity, and strategic litigation considerations. As courts refine their interpretation of the BPCIA, biosimilar entrants and patent holders must navigate a complex, high-stakes environment to balance market access with intellectual property protections.
By diligently managing patent disclosures, understanding procedural nuances, and preparing for extended legal battles, stakeholders can optimize their positions in this competitive and rapidly evolving sector.
